Company news

Praxis Precision Medicines, Inc. news in 2021

Praxis Precision Medicines, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021

December 9, 2021

Praxis Precision Medicines Announces Management Team Appointments

December 1, 2021

Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting

November 28, 2021

Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference

November 23, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 2, 2021

Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021

October 21, 2021

Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference

August 31, 2021

Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms

August 15, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 15, 2021

Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference

August 1, 2021

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

June 21, 2021

Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer

May 24, 2021

Praxis Precision Medicines Prices Public Offering of Common Stock

May 12, 2021

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 10, 2021

Praxis Precision Medicines Announces Proposed Public Offering of Common Stock

May 10, 2021

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE

April 29, 2021

Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.

April 28, 2021

Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.

April 14, 2021

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE

April 13, 2021

Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day

March 23, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

March 16, 2021

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021

March 14, 2021

Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development

February 15, 2021

Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs

January 6, 2021

Calls in 2021

Decks in 2021